Macrogol (Polyethylene Glycol)
Brand names: Movicol, Laxido, CosmoCol
Macrogol (polyethylene glycol) is an osmotic laxative, taken as oral powder dissolved in water, used to treat chronic constipation and faecal impaction.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Macrogol is an inert polymer that binds water osmotically and is not absorbed or metabolised, so it retains fluid within the bowel to increase stool volume and soften it, stimulating peristalsis and bowel evacuation.
Prescribing in practice
- It is contraindicated in intestinal obstruction or perforation, ileus and severe inflammatory bowel conditions such as toxic megacolon, where stimulating bowel transit is dangerous.
- Higher-volume regimens used for faecal impaction can cause fluid and electrolyte shifts, so caution is needed in frail, elderly or cardiovascularly impaired patients and adequate hydration is important.
- Each sachet must be dissolved in the recommended volume of water before drinking to ensure the osmotic balance is correct.
Monitoring
Routine monitoring is not usually required, but consider fluid and electrolyte status when high doses are used for impaction or in vulnerable patients.
Counselling the patient
- Dissolve each sachet fully in water before drinking and keep up your overall fluid intake.
- When used to clear a blockage of hardened stool you may need to drink several sachets over the day as directed.
Evidence & guidelines
NICE recommends macrogols as a first-line osmotic laxative for chronic constipation and for the treatment of faecal impaction.
Reference: NICE NG128 Constipation; NICE CG99 Constipation in Children; SPC Movicol; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021